GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Other Net Income (Loss)

Inventiva (Inventiva) Other Net Income (Loss) : $-0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Inventiva Other Net Income (Loss)?

Inventiva's Other Net Income (Loss) for the six months ended in Dec. 2023 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00 Mil.

Inventiva's quarterly Other Net Income (Loss) declined from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($-0.00 Mil) but then increased from Jun. 2023 ($-0.00 Mil) to Dec. 2023 ($0.00 Mil).

Inventiva's annual Other Net Income (Loss) declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) and declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

Inventiva Other Net Income (Loss) Historical Data

The historical data trend for Inventiva's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva Other Net Income (Loss) Chart

Inventiva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Inventiva Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Inventiva Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Inventiva's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Inventiva (Inventiva) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (NAS:IVA) » Definitions » Other Net Income (Loss)
Comparable Companies
XPAR:AELIS XPAR:IPH XPAR:DBV XPAR:MEDCL XPAR:NANO XPAR:GNFT XPAR:TNG XPAR:ALSEN XPAR:ADOC XPAR:OSE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IVA:France 6IV:Germany
Address
50 rue de Dijon, Daix, FRA, 21121
Website
https://www.inventivapharma.com
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Most of the group's revenue is derived from its research partnerships with AbbVie and BI.